Evidence map›Paper›PMID 38380271›Full record

ArticleFrontiers in molecular biosciences2023

The potential of N2-modified cap analogues for precise genetic manipulation through mRNA engineering.

Karol Kurpiejewski, Anna Stankiewicz-Drogon, Karolina Piecyk, Eliza Rajkowska, Paulina Skrzypczyk, Jingping Geng, Edward Darzynkiewicz, Renata Grzela, Marzena Jankowska-Anyszka

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in molecular biosciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Application of Mammalian Nudix Enzymes to Capped RNA Analysis.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Karol KurpiejewskiFaculty of Chemistry, University of Warsaw, Warsaw, Poland.
Anna Stankiewicz-DrogonDivision of Biophysics, Institute of Experimental Physics, Faculty of Physics, University of Warsaw, Warsaw, Poland.
Karolina PiecykFaculty of Chemistry, University of Warsaw, Warsaw, Poland.
Eliza RajkowskaFaculty of Chemistry, University of Warsaw, Warsaw, Poland.
Paulina SkrzypczykFaculty of Chemistry, University of Warsaw, Warsaw, Poland.
Jingping GengCentre of New Technologies, University of Warsaw, Warsaw, Poland.
Edward DarzynkiewiczCentre of New Technologies, University of Warsaw, Warsaw, Poland.
Renata GrzelaDivision of Biophysics, Institute of Experimental Physics, Faculty of Physics, University of Warsaw, Warsaw, Poland.
Marzena Jankowska-AnyszkaFaculty of Chemistry, University of Warsaw, Warsaw, Poland.
University of Warsaw · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The technology of mRNA-based drugs is currently being intensively developed and implemented. Medical products of this type are already being used as viral vaccines and could potentially find application in a wide range of diseases. The tremendous interest in mRNA is due to the relatively easy production process, which can be quickly adapted to meet societal needs. The properties of this molecule depend on the structure of its individual components, such as the structure of the cap at the 5' end. Modifications of the cap significantly affect the translational potential and lifespan of the whole mRNA. In the current work, we present the synthesis of derivatives of cap analogues modified at the N2 position of 7-methylguanosine. In addition to the substituent at the N2 position, the derivatives had either an extended triphosphate chain, a thiophosphate modification, an added cap1-modified nucleotide or an extended linker between the substituent and 7-methylguanosine. The compounds were tested for use as translation inhibitors and as components for mRNA preparation and appeared of interest for both applications.

Indexed as

cap analoguesmRNA-based drugsmRNA engineeringmRNA technologymRNA therapeutics

Identifiers

PMID38380271
PMCPMC10878308
OpenAlexW4391564245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.